TP Biosciences offers high-quality biosimilars, which are biologic medicines highly similar to FDA- and EMA-approved reference biologics. These products provide cost-effective alternatives for research and preclinical development while maintaining comparable safety, efficacy, and purity to originator biologics.

Key Features of TP Biosciences Biosimilars:

High Purity & Bioactivity – Rigorous characterization ensures similar function to reference biologics.
Produced in Mammalian Expression Systems – Ensures proper folding, glycosylation, and stability.
Batch-to-Batch Consistency – Stringent QC testing for reliable results.
Low Endotoxin Levels (0.1-1 EU/µg) – Suitable for in vitro and in vivo applications.
Custom & Bulk Production Available – Supports biopharmaceutical development.

Product Categories & Applications:

1. Oncology & Immunotherapy Biosimilars

• Bevacizumab (Avastin® Biosimilar) – Anti-VEGF monoclonal antibody for cancer therapy.
• Trastuzumab (Herceptin® Biosimilar) – HER2-targeting antibody for breast cancer research.
• Rituximab (Rituxan® Biosimilar) – Anti-CD20 antibody for lymphoma and autoimmune diseases.
• Nivolumab & Pembrolizumab (Opdivo® & Keytruda® Biosimilars) – PD-1 inhibitors for checkpoint blockade research.
• Atezolizumab (Tecentriq® Biosimilar) – Anti-PD-L1 monoclonal antibody.

2. Autoimmune & Inflammatory Disease Biosimilars

• Adalimumab (Humira® Biosimilar) – Anti-TNF-α for rheumatoid arthritis and IBD research.
• Infliximab (Remicade® Biosimilar) – TNF-α inhibitor for autoimmune disease models.
• Tocilizumab (Actemra® Biosimilar) – IL-6 receptor antagonist for inflammation studies.

3. Hematology & Growth Factor Biosimilars

• Erythropoietin (EPO, Epogen®/Procrit® Biosimilar) – Stimulates red blood cell production.
• Filgrastim & Pegfilgrastim (Neupogen® & Neulasta® Biosimilars) – G-CSF for neutropenia treatment research.
• Darbepoetin Alfa (Aranesp® Biosimilar) – Long-acting EPO analog.

4. Hormones & Metabolic Biosimilars

• Insulin Glargine & Insulin Lispro (Lantus® & Humalog® Biosimilars) – Diabetes research applications.
• Teriparatide (Forteo® Biosimilar) – Parathyroid hormone analog for osteoporosis research.

5. Ophthalmology Biosimilars

• Ranibizumab (Lucentis® Biosimilar) – Anti-VEGF therapy for retinal diseases.
• Aflibercept (Eylea® Biosimilar) – VEGF-Trap fusion protein for age-related macular degeneration research.